Cargando…

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres

BACKGROUND: Oral cladribine has been approved for the treatment of relapsing multiple sclerosis (MS) yet real-world evidence regarding its effectiveness and safety remains scarce. OBJECTIVE: To evaluate efficacy and safety outcomes of MS patients following induction of cladribine. METHODS: We evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfeuffer, Steffen, Rolfes, Leoni, Hackert, Jana, Kleinschnitz, Konstanze, Ruck, Tobias, Wiendl, Heinz, Klotz, Luisa, Kleinschnitz, Christoph, Meuth, Sven G, Pul, Refik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795224/ https://www.ncbi.nlm.nih.gov/pubmed/33975489 http://dx.doi.org/10.1177/13524585211012227

Ejemplares similares

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitis
por: Schroeter, Christina B., et al.
Publicado: (2022)

Immunotherapies in chronic adhesive arachnoiditis - A case series and literature review
por: Hackert, Jana, et al.
Publicado: (2021)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Natural Killer Cells Are Present in Rag1(−/−) Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke
por: Rolfes, Leoni, et al.
Publicado: (2021)

Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
por: Korsen, Melanie, et al.
Publicado: (2022)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
por: Gold, Ralf, et al.
Publicado: (2021)

The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders—A Systematic Review
por: Göbel, Kerstin, et al.
Publicado: (2018)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Two pore domain potassium channels in cerebral ischemia: a focus on K(2P)9.1 (TASK3, KCNK9)
por: Ehling, Petra, et al.
Publicado: (2010)

Correction: Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9)
por: Ehling, Petra, et al.
Publicado: (2013)

Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS
por: Möhn, Nora, et al.
Publicado: (2020)

Impact of NKG2D Signaling on Natural Killer and T‐Cell Function in Cerebral Ischemia
por: David, Christina, et al.
Publicado: (2023)

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?
por: Pawlitzki, Marc, et al.
Publicado: (2019)

Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency
por: Pfeuffer, Steffen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_emb7v419chl6htn1i001u98rrf